Teva Aims to Derail Approval of Biogen Idec's MS Pill
Can Biogen Idec’s (NASDAQ:BIIB) promising multiple sclerosis pill be derailed -- or at least delayed -- by a rival drug maker? The big Israeli drug company Teva Pharmaceutical Industries (NYSE:TEVA) petitioned the US Food and Drug Administration to hold off on approving Biogen’s experimental MS drug known as BG-12 until medical experts can convene to review the safety of the treatment. The FDA is scheduled to make an approval decision on BG-12 by the end of March. Teva which sells the MS drug Copaxone says in its “citizen petition” to the FDA that “it is especially important for the ...
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here